Navigation Links
Failure Rate of DePuy ASR XL Hip Implant Rising
Date:3/31/2011

FORT WORTH, Texas, March 31, 2011 /PRNewswire/ -- Recent information presented at the British Hip Society Annual Conference held from March 2 -4, 2011 indicates a rise in the failure rate of the DePuy ASR XL Acetabular Hip Replacement System which was manufactured and marketed by DePuy Orthopaedics, Inc., a subsidiary of Johnson & Johnson.  The British Orthopaedic Association has released a summary of the results of the study presented, stating that the early failure rates "range from 21% revision rate at 4 years (potentially rising to 35% if all currently known painful implants progress to revision) to 49% at 6 years for the ASR XL device."  This summary was included in an article published on the British Orthopaedic Association's website entitled "Large Diameter Metal on Metal Bearing Total Hip Replacements."

"The DePuy ASR XL Hip Replacement Systems were first sold by DePuy and Johnson & Johnson in the UK and other countries in 2003. The ASR XL was sold in the United States beginning in 2005. It now appears that patients who received these implants are experiencing failures at a staggering rate. The device was recalled by DePuy Orthopaedics, Inc. on August 24, 2010. Sales of a medical product with a failure rate of 49% at six years is unconscionable. Profits over patient safety is unacceptable," said attorney John David Hart of the Law Offices of John David Hart who represents many individuals in the United States who have been injured as a result of this defective hip replacement system.

DePuy identified reasons for the failure of the hip replacement system as component loosening, component malalignment, infection, fracture of the bone, dislocation, metal sensitivity and pain. Additional complications from the DePuy ASR XL Acetabular Hip Replacement System may include increased metal ion levels in the blood, bone staining, necrosis, swelling, nerve damage, tissue damage and/or muscle damage.

The Law Offices of John David Hart is a group of experienced and dedicated legal professionals working to protect the rights of people wronged by the acts of others.  Across the country, the firm represents individuals in cases of catastrophic personal injury, wrongful death, dangerous drugs and medical products, automobile and truck accidents and oil and gas litigation.  For more information, please contact John David Hart at 800.961.4278 or johnhart@hartlaw.com or visit www.hiprecallinfo.com.


'/>"/>
SOURCE The Law Offices of John David Hart
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Qualitest Receives FDA Approval for Toresmide Tablets (Generic Demadex®) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease
2. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
4. Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease
5. Success Factors and Failure Points in Biopharmaceutical Product Launches
6. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products
10. NT-proBNP Guided Therapy Keeps Heart Failure Patients out of the Hospital Through a Reduction in Cardiovascular Events
11. Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
Breaking Medicine News(10 mins):